The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes
Alex C Spyropoulos1, Sharyl Magnuson1, Sei Keng Koh21Clinical Thrombosis Center, Lovelace Medical Center, Albuquerque, NM, USA; 2Department of Pharmacy, Singapore General Hospital, SingaporeAbstract: Heparin-induced thrombocytopenia (HIT) is an immunologic drug reaction characterized by paradoxical...
Main Authors: | Alex C Spyropoulos, Sharyl Magnuson, Sei Keng Koh |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2008-06-01
|
Series: | Therapeutics and Clinical Risk Management |
Online Access: | http://www.dovepress.com/the-use-of-fondaparinux-for-the-treatment-of-venous-thromboembolism-in-a1892 |
Similar Items
-
Failure of Fondaparinux in Autoimmune Heparin-Induced Thrombocytopenia
by: Michelangelo Sartori, et al.
Published: (2020-10-01) -
Fondaparinux monitoring in a patient with heparin-induced thrombocytopenia on hemodialysis
by: Kušić Jovana, et al.
Published: (2016-01-01) -
Low-molecular-weight heparins in the treatment of venous thromboembolism
by: Huisman Menno V, et al.
Published: (2000-08-01) -
Short insight of pediatric cerebral venous thrombosis and the safety of intra-arterial heparin flushing as a new therapeutic method
by: Ardianto Pramono, et al.
Published: (2019-08-01) -
Why differentiate low molecular weight heparins for venous thromboembolism?
by: Walenga Jeanine M, et al.
Published: (2007-06-01)